8 February, 2023
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
20 October, 2022
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
08 ApRil, 2022
T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting
If you are a member of the media and would like to speak with T-knife, please contact us at email@example.com.